{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:30:10Z","timestamp":1788388210020,"version":"build-2803163510"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Brodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family. It has been approved for the treatment of moderate-to-severe plaque psoriasis after being evaluated in three Phase-3 trials. However, long-term data on brodalumab in a real-life setting are still limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The aim of this study was to evaluate the long-term effectiveness and safety of brodalumab in psoriasis. We also assessed the drug survival of brodalumab in a 3\u2009years timespan. We conducted a retrospective multicenter study on 606 patients followed up at 14 Italian dermatology units, all treated with brodalumab according to Italian guidelines. Patients\u2019 demographics and disease characteristics were retrieved from electronic databases. At baseline and weeks 12, 24, 52, 104 and 156, we evaluated the psoriasis area and severity index (PASI) score and investigated for adverse events. The proportions of patients reaching 75, 90 and 100% (PASI 75, PASI 90 and PASI 100, respectively) improvement in PASI, compared with baseline, were also recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At week 12, 63.53% of the patients reached PASI 90 and 49.17% PASI 100. After 3\u2009years of treatment, 65.22% of patients maintained a complete skin clearance, and 91.30% had an absolute PASI of 2 or less. Patients na\u00efve to biological therapies had better clinical responses at weeks 12, 24 and 52. However, after 2\u2009years of treatment, no significant differences were observed. Body mass index did not interfere with the effectiveness of brodalumab throughout the study. No new safety findings were recorded. After 36\u2009months, 85.64% of our patients were still on treatment with brodalumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our data confirm the effectiveness and the safety of brodalumab in the largest real-life cohort to date, up to 156\u2009weeks.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1196966","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T05:48:05Z","timestamp":1688363285000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3\u2009years multicenter retrospective study\u2014IL PSO (Italian landscape psoriasis)"],"prefix":"10.3389","volume":"10","author":[{"given":"Luigi","family":"Gargiulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Amoruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Argenziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Giovanni","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Gaiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lasagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sampogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Travaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.36849\/jdd.6040","article-title":"An overview of biologics for psoriasis","volume":"20","author":"Dave","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/14712598.2022.2100219","article-title":"Pathogenesis-oriented therapy of psoriasis using biologics","volume":"22","author":"Boehncke","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/jdv.18594","article-title":"Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52\u2009weeks multicentre retrospective study-IL PSO (Italian landscape psoriasis)","volume":"37","author":"Narcisi","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e12946","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis-head-to-head trials comparing different biologics in psoriasis treatment","volume":"92","author":"Ten Bergen","year":"2020","journal-title":"Scand J Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/jdv.18913","article-title":"Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104\u2009weeks multicenter retrospective study\u2014IL PSO (Italian landscape psoriasis)","volume":"37","author":"Gargiulo","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cei.13449","article-title":"IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa","volume":"201","author":"Fletcher","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/bjd.18013","article-title":"Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study","volume":"181","author":"Papini","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/14712598.2020.1729736","article-title":"Ixekizumab for the treatment of psoriasis: up-to-date","volume":"20","author":"Craig","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e15952","DOI":"10.1111\/dth.15952","article-title":"Sub-erythrodermic psoriasis successfully treated with bimekizumab: a case report","volume":"35","author":"Valenti","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-018-0888-4","article-title":"Brodalumab: a review in moderate to severe plaque psoriasis","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1080\/09546634.2022.2125265","article-title":"Brodalumab efficacy in bio-na\u00efve psoriasis patients: real-life experience of 202 subjects up to 48\u2009weeks","volume":"33","author":"Mastorino","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1080\/09546634.2022.2082354","article-title":"Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors\u2014brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry","volume":"33","author":"Kojanova","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/jdv.18825","article-title":"Brodalumab in plaque psoriasis: real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104\u2009weeks","volume":"37","author":"Rompoti","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23736\/S2784-8671.21.07132-2","article-title":"Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis","volume":"157","author":"Gisondi","year":"2022","journal-title":"Ital J Dermatol Venerol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jaad.2019.05.095","article-title":"Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120\u2009weeks results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial","volume":"82","author":"Puig","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/jdv.16931","article-title":"Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience","volume":"35","author":"Fargnoli","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e15667","DOI":"10.1111\/dth.15667","article-title":"Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting","volume":"35","author":"Megna","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s13555-022-00795-x","article-title":"Real-life effectiveness and safety of Risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52\u2009weeks retrospective study","volume":"12","author":"Gargiulo","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"ii20","DOI":"10.1093\/ecco-jcc\/jjac023","article-title":"What can IBD specialists learn from IL-23 trials in dermatology?","volume":"16","author":"Valenti","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/jdv.16254","article-title":"Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review","volume":"34","author":"Fowler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s13555-022-00726-w","article-title":"Safety of biologic therapies in patients with moderate-to-severe plaque psoriasis and concomitant viral hepatitis: a monocentric retrospective study","volume":"12","author":"Gargiulo","year":"2022","journal-title":"Dermatol Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1196966\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T05:48:07Z","timestamp":1688363287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1196966\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":25,"alternative-id":["10.3389\/fmed.2023.1196966"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1196966","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"article-number":"1196966"}}